BioCryst Pharmaceuticals Inc (MEX:BCRX)
MXN 170 0 (0%) Market Cap: 31.93 Bil Enterprise Value: 41.42 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

Q4 2022 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Feb 21, 2023 / 01:30PM GMT
Release Date Price: MXN215
Operator

Good morning, and welcome to the BioCryst Fourth Quarter 2022 Earnings Conference Call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thanks, Andrea. Good morning, and welcome to BioCryst's Fourth Quarter and Year-end 2022 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot